Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2022-09-27 Interim / Quarterly Rep…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Interim Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 INTERIM REPORT' and contains detailed financial highlights, management discussion and analysis, corporate information, and interim condensed consolidated financial statements. It covers a six-month period ending June 30, 2022, which is typical for an interim or quarterly report. The content includes unaudited financial data, management commentary on business progress, and pipeline updates, all consistent with an interim financial report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-27 English
INTERIM REPORT 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 Interim Report' and contains detailed financial statements including condensed consolidated statements of profit or loss, financial position, changes in equity, cash flows, notes to the financial statements, and management discussion and analysis for the six months ended 30 June 2022. It references compliance with HKAS 34 'Interim Financial Reporting' and includes unaudited financial data for the half-year period. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-21 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. providing a business update about the termination of a promotion service agreement with Roche Pharma China. It does not contain financial statements, detailed financial analysis, or regulatory certifications. The document is relatively short (3206 characters) and serves to inform shareholders and investors about a specific business development rather than presenting a full report or financial results. There is no indication that this is an earnings release, annual or interim report, or any other formal regulatory filing. It is a business update announcement, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-09-16 English
VOLUNTARY ANNOUNCEMENT - SHANGHAI PUBLIC HEALTH CLINICAL CENTER COMPLETED PATIENT ENROLLMENT IN CLINICAL STUDY OF PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) IN COMBINATION WITH CHIDAMIDE FOR FUNCTIONAL CURE O
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the completion of patient enrollment in a clinical study for a drug candidate. It provides details about the clinical trial design, the drug's mechanism, and a cautionary statement. There are no financial statements, regulatory certifications, voting results, or management changes. The document is relatively short (3482 characters) and serves as a business update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is an announcement about a clinical trial progress, which is a business development update. Given the available categories, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-09-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, share options, and other related share capital information for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules under Chapter 19B. The content focuses on share capital movements, share options, and confirmations related to securities listed on the Stock Exchange of Hong Kong (SEHK). There is no financial performance data, earnings information, or management discussion. The document is a regulatory submission related to share capital and securities movements rather than a financial report or announcement of voting results. This type of filing aligns with regulatory filings that report compliance and share capital movements to the exchange but do not constitute a full financial report or announcement of a meeting result. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (5808 characters) and detailed tabular data support it being a substantive regulatory filing rather than a brief announcement or report publication notice.
2022-09-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on authorized and issued shares, share options, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, providing updates on share capital and share movements rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a report like an annual or interim report. It is also not a simple announcement or certification but a formal regulatory submission detailing share capital movements. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-09-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.